news.vumc.org
Study identifies potential noninvasive blood marker for Crohn's disease activity
The study suggests a blood cytokine (CXCL9) could help noninvasively detect intestinal inflammation in Crohn’s disease, which might one day reduce reliance on colonoscopy for monitoring disease activity.
Adults with Crohn’s disease, gastroenterology clinicians, and researchers working on IBD biomarkers or immune pathways.
What To Know
Researchers at Vanderbilt measured multiple serum cytokines in 103 people with Crohn’s disease and 40 non-IBD controls undergoing colonoscopy, comparing clinical, endoscopic and histologic activity.
They report that several cytokines differed by disease activity and highlight CXCL9 as the cytokine with the best ability to discriminate active from inactive Crohn’s disease on endoscopic and histologic assessment. The study is reported in Scientific Reports and is presented as an early step toward a noninvasive blood marker for intestinal inflammation.
This article summarizes published research rather than giving clinical recommendations. It emphasizes a potential blood biomarker (CXCL9) that correlated with endoscopic and histologic activity in this cohort, but does not report that CXCL9 is validated for routine clinical use.
If you’re interested in the original data and methods, the Vanderbilt news item cites the Scientific Reports paper and the study authors.
If you have Crohn’s disease, this finding may be promising because noninvasive markers could reduce the need for frequent endoscopy in some settings, but more validation in larger and diverse cohorts is typically required before changes to clinical monitoring are adopted.
This is an early clinical research report comparing cytokine levels with clinical, endoscopic and histologic scores in a single-center cohort; the article does not claim CXCL9 is ready for clinical use. Larger validation studies and regulatory steps would be needed before a new blood test changes routine care.
